<DOC>
	<DOCNO>NCT03079050</DOCNO>
	<brief_summary>Dexlansoprazole modify release ( MR ) , R-enantiomer Lansoprazole , FDA approve drug ( 2009 ) management erosive esophagitis nonerosive reflux disease 1 . Dexlansoprazole unique dual delayed-release delivery system design address unmet need may accompany traditional proton pump inhibitor , two separate pH-depended release phase , first proximal duodenum second distal small intestine . This dual release system extend plasma concentration pharmacodynamics effect beyond single-release PPIs , allow dosing time day without regard meal 1 . A study conduct Fass et al . show use dexlansoprazole MR 30 mg patient symptomatic GERD significantly effective placebo improve nocturnal heartburn , reduce GERD-related sleep disturbance , consequently improve work productivity , sleep quality quality life 2 . Because pharmacokinetic property , Dexlansoprazole modify release ( MR ) may prove beneficial optimizing management GERD associate burden often surface heavy evening Suhur meal , increase nocturnal symptom poor sleep quality .</brief_summary>
	<brief_title>A Controlled Trial Dexlansoprazole 30mg vs. Dexlansoprazole 60mg Relief Heartburn During Fasting Month Ramadan</brief_title>
	<detailed_description>To investigate efficacy quality life improvement Dexlansoprazole 60mg versus traditional PPI ( Dexlansoprazole 30 mg ) take daily Iftar time patient know symptomatic heartburn exacerbate Ramadan daily treatment .</detailed_description>
	<mesh_term>Heartburn</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<criteria>Individuals 1875 year old Fasting Ramadan No daily PPI use Individuals willing sign consent form Patients own smartphone able use smartphone application Known erosive GERD PPI Pregnant females Prior gastric surgery Long standing diabetes mellitus ( â‰¥10 year disease ) Frequent NSAID use ( &gt; 3x/week ) Morbid obesity ( BMI &gt; 35 ) History recent ( &lt; 6 month ) upper GI bleed Patients smartphone use smartphone application Known allergy PPIs Known history poor compliance adherence active psychological problem might impact adherence</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>